Phathom Pharmaceuticals, Inc. PHAT Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s contract liabilities, non-current?
- Phathom Pharmaceuticals, Inc. (PHAT) reported contract liabilities, non-current of $347.9M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s contract liabilities, non-current changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s contract liabilities, non-current increased by 1.2% year-over-year, from $343.81M to $347.9M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s contract liabilities, non-current?
- Over 3 years (2022 to 2025), Phathom Pharmaceuticals, Inc.'s contract liabilities, non-current has grown at a 47.3% compound annual growth rate (CAGR), from $109.53M to $350.12M.